Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: aprea.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/20/2021 | Neutral → Underweight | JP Morgan | |
8/16/2021 | Buy → Hold | Berenberg | |
8/16/2021 | $6.00 → $4.00 | Neutral | HC Wainwright & Co. |
8/13/2021 | $6.00 → $5.00 | Sector Perform | RBC Capital |
8/13/2021 | $5.00 → $3.00 | Equal-Weight → Underweight | Morgan Stanley |
DOYLESTOWN, Pa., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. Presentation Details DATE: September 19thTIME: 10.30 – 11am ETLINK: https://bit.ly/3XjDJkL This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will deliver an in-person presentation at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY. Details are as follows: H.C. Wainwright 26th Annual Global Investment Conference Date:September 10, 2024Time:9am ETLocation:Holmes II, Lotte New York Palace HotelWebcast:click here The webcast will also be archived on Aprea's corporate we
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York, NY. Details are as follows: H.C. Wainwright 26th Annual Global Investment Conference Date:September 9-11, 2024Location:New York, NYWebcast:click here The above presentation is available to access "on-demand", beginning at 7:00 A.M. (ET), on September 9,
DOYLESTOWN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York, NY. Details are as follows: H.C. Wainwright 26th Annual Global Investment Conference Date:September 9-11, 2024Location:New York, NYWebcast:click here The above presentation is available to access "on-demand", beginning at 7:00 A.M. (ET), on September 9,
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL event to discuss APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor, on Monday, June 24, 2024 at 9:00 AM ET. To register, click here. The webinar will feature Joseph Vacca, PhD, Medicinal Chemistry Expert and Consultant to Aprea, who will discuss the medicinal chemistry history, highly selective drug design, and preclinical findings of APR-1051. It will also feature Eric J. Brown, PhD (Unive
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows: 2024 RBC Capital Markets Global Healthcare ConferenceDate:May 14-15, 2024Location:New York, NY Management will be available for one-on-one meetings. To request a meeting, please contact your conference representative. About Aprea Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical co
DOYLESTOWN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer (CMO) of the Company, effective May 1, 2024. Dr. Mirza has been an integral part of the Company's senior team as a consultant since February, 2023 and will now assume a more central role in leading the Company's development of its expanding clinical pipeline. "Aprea is at a critical point of enriching and expanding its clinical programs. Dr. Mirza has already made significant contribu
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented ATRN-119, a novel macrocyclic ATR inhibitor, continues to appear safe and well tolerated with no Dose Limiting Toxicities observed in ongoing Phase 1/2a study; preliminary signs of clinical benefit reported; enrollment in the study continues DOYLESTOWN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0 million in total gross proceeds DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certai
S-8 - Aprea Therapeutics, Inc. (0001781983) (Filer)
8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)
8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)
424B3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
EFFECT - Aprea Therapeutics, Inc. (0001781983) (Filer)
ARS - Aprea Therapeutics, Inc. (0001781983) (Filer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
3 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.
Features Medicinal Chemistry Expert Joseph Vacca And University Of Pennsylvania's Eric J. Brown Discussing Preclinical Findings
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024Through the first 5 cohorts, ATRN-119 has been found to be safe and well tolerated with no dose limiting toxicities (DLTs) observed
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.78) by 14.1 percent. This is a 50 percent increase over losses of $(1.34) per share from the same period last year. The company reported $380.57 thousand in sales this quarter.
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presentedATRN-119, a novel macrocyclic ATR inhibitor, continues to appear safe and well tolerated with no Dose Limiting Toxicities observed in ongoing Phase 1/2a study; preliminary signs of clinical benefit reported; enrollment in the study continuesDOYLESTOWN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focuse
Gainers Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ:CADL) shares rose 27.97% to $2.15. The company's market cap stands at $63.0 million. Healthcare Triangle (NASDAQ:HCTI) stock rose 23.56% to $2.36. The company's market cap stands at $10.9 million. SINTX Techs (NASDAQ:SINT) stock increased by 19.56% to $0.03. The market value of their outstanding shares is at $1.4 million. Addex Therapeutics (NASDAQ:ADXN) shares increased by 16.84% to $18.0. The company's market cap stands at $19.0 million. Novo Integrated Sciences (NASDAQ:NVOS) shares mo
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
DOYLESTOWN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer (CMO) of the Company, effective May 1, 2024. Dr. Mirza has been an integral part of the Company's senior team as a consultant since February, 2023 and will now assume a more central role in leading the Company's development of its expanding clinical pipeline. "Aprea is at a critical point of enriching and expanding its clinical programs. Dr. Mirza has already made significant contribu
DOYLESTOWN, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it has appointed Dr. Jean-Pierre Bizzari to its Board of Directors and is naming Dr. Richard Peters as its new Chairman of the Board. Dr. Bizzari will replace Mr. Christian Schade, who is stepping down from the Board. "We warmly welcome Dr. Jean-Pierre Bizzari to our Board of Directors. Jean-Pierre is an esteemed industry thought leader and was the Group Head Clinical Development Oncology at Celgene where he was responsible for developing some of the most
DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gabriela Gruia, M.D. to its Board of Directors, effective as of May 5, 2023. Dr. Gruia joins Aprea with over 25 years of clinical, regulatory and life science leadership experience. "We are honored to welcome Dr. Gruia to the Aprea Board of Directors, where her deep experience and accomplishments in drug development and regulatory affairs will be of immense importance in advanci
SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13D/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13D/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13D/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)
SC 13D/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight
Berenberg downgraded Aprea Therapeutics from Buy to Hold
HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously
RBC Capital reiterated coverage of Aprea Therapeutics with a rating of Sector Perform and set a new price target of $5.00 from $6.00 previously
Morgan Stanley downgraded Aprea Therapeutics from Equal-Weight to Underweight and set a new price target of $3.00 from $5.00 previously
RBC Capital reiterated coverage of Aprea Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $10.00 previously
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update: On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i